BR9907269A - Agente de transferência de ácidos nucleicos, composição, utilização de um agente de transferência, e, processos de transferência de ácidos nucleicos nas células, de preparação de uma composição e de tratamento de doenças. - Google Patents

Agente de transferência de ácidos nucleicos, composição, utilização de um agente de transferência, e, processos de transferência de ácidos nucleicos nas células, de preparação de uma composição e de tratamento de doenças.

Info

Publication number
BR9907269A
BR9907269A BR9907269-6A BR9907269A BR9907269A BR 9907269 A BR9907269 A BR 9907269A BR 9907269 A BR9907269 A BR 9907269A BR 9907269 A BR9907269 A BR 9907269A
Authority
BR
Brazil
Prior art keywords
composition
nucleic acid
transfer agent
agent
cells
Prior art date
Application number
BR9907269-6A
Other languages
English (en)
Inventor
Gerardo Byk
Catherine Dubertret
Bruno Pitard
Daniel Scherman
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9801065A external-priority patent/FR2774394B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BR9907269A publication Critical patent/BR9907269A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"AGENTE DE TRANSFERêNCIA DE áCIDOS NUCLEICOS, COMPOSIçãO, UTILIZAçãO DE UM AGENTE DE TRANSFERêNCIA, E, PROCESSOS DE TRANSFERêNCIA DE áCIDOS NUCLEICOS NAS CéLULAS, DE PREPARAçãO DE UMA COMPOSIçãO E DE TRATAMENTO DE DOENçAS". A presente invenção refere-se a um novo agente para a transferência de ácidos nucleicos nas células. Este agente é mais particularmente caracterizado em que ele comporta uma ou várias pontes dissulfeto sensíveis às condições redutoras. A invenção refere-se igualmente às composições compreendendo um tal agente, e suas utilizações para a transferência in vitro, in vivo ou ex vivo ácidos nucleicos de interesse nos diferentes tipos celulares.
BR9907269-6A 1998-01-30 1999-01-28 Agente de transferência de ácidos nucleicos, composição, utilização de um agente de transferência, e, processos de transferência de ácidos nucleicos nas células, de preparação de uma composição e de tratamento de doenças. BR9907269A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9801065A FR2774394B1 (fr) 1998-01-30 1998-01-30 Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
US7702698P 1998-03-06 1998-03-06
PCT/FR1999/000162 WO1999038821A2 (fr) 1998-01-30 1999-01-28 Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications

Publications (1)

Publication Number Publication Date
BR9907269A true BR9907269A (pt) 2001-04-03

Family

ID=26234096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907269-6A BR9907269A (pt) 1998-01-30 1999-01-28 Agente de transferência de ácidos nucleicos, composição, utilização de um agente de transferência, e, processos de transferência de ácidos nucleicos nas células, de preparação de uma composição e de tratamento de doenças.

Country Status (14)

Country Link
US (1) US6521252B1 (pt)
EP (1) EP1049793B1 (pt)
JP (1) JP2002501762A (pt)
KR (1) KR20010081924A (pt)
CN (1) CN1289371A (pt)
AT (1) ATE306556T1 (pt)
AU (1) AU759197B2 (pt)
BR (1) BR9907269A (pt)
CA (1) CA2318512C (pt)
DE (1) DE69927669T2 (pt)
HU (1) HUP0101393A3 (pt)
IL (1) IL137247A0 (pt)
NO (1) NO20003880L (pt)
WO (1) WO1999038821A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US6379698B1 (en) 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
WO2002028367A1 (fr) * 2000-10-04 2002-04-11 Kyowa Hakko Kogyo Co., Ltd. Procede de revetement de particules fines avec un film de lipides
EP2207570A2 (en) * 2007-09-14 2010-07-21 Nitto Denko Corporation Drug carriers
FR2921369B1 (fr) * 2007-09-25 2014-07-11 Pf Medicament Nouveau procede de preparation de derives (poly) aminoalkylaminoacetamide d'epipodophyllotoxine,utiles pour leurs applications en therapeutique comme agent anticancereux.
GB0720486D0 (en) * 2007-10-19 2007-11-28 Univ Edinburgh Cationic lipids
WO2014134445A1 (en) * 2013-02-28 2014-09-04 Tufts Unversity Disulfide compounds for delivery of pharmaceutical agents
US11433128B2 (en) * 2017-04-07 2022-09-06 Tianxin Wang Cell surface anchoring antigen conjugates to treat cancer
CN111918668A (zh) * 2018-02-16 2020-11-10 王天欣 ***细胞和癌症的方法和药剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
EP0537299A1 (en) 1990-03-29 1993-04-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
JPH11507031A (ja) 1995-06-07 1999-06-22 ジェン−プローブ・インコーポレーテッド チオカチオン性脂質，医薬組成物およびその使用方法
FR2741066B1 (fr) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP0945138A1 (en) 1997-12-04 1999-09-29 Université Louis Pasteur de Strasbourg Transfection particles
US6169078B1 (en) 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances

Also Published As

Publication number Publication date
NO20003880D0 (no) 2000-07-28
NO20003880L (no) 2000-07-28
AU4384300A (en) 2001-04-05
CN1289371A (zh) 2001-03-28
EP1049793A2 (fr) 2000-11-08
ATE306556T1 (de) 2005-10-15
DE69927669T2 (de) 2006-07-20
HUP0101393A3 (en) 2004-10-28
IL137247A0 (en) 2001-07-24
AU759197B2 (en) 2003-04-10
US6521252B1 (en) 2003-02-18
WO1999038821A2 (fr) 1999-08-05
KR20010081924A (ko) 2001-08-29
DE69927669D1 (de) 2006-02-23
JP2002501762A (ja) 2002-01-22
WO1999038821A3 (fr) 1999-09-23
EP1049793B1 (fr) 2005-10-12
CA2318512A1 (fr) 1999-08-05
CA2318512C (fr) 2009-10-13
HUP0101393A1 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
DE69635609D1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
BR0213213A (pt) composições farmacêuticas pró-micela
BR0016341A (pt) Fórmula para bebês, processo para preparar um hidrolisado protéico, hidrolisado protéico, e, uso de um hidrolisado protéico
BR9812018A (pt) Composições farmacêuticas de meloxicam com solubilidade e biodisponibilidade melhoradas
BRPI9710372B8 (pt) composto, e, composição farmacêutica.
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
BR0109983A (pt) Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
BR9810450A (pt) Derivados de ácido barbitúrico com atividade antimetastática e antitumor
BR9907269A (pt) Agente de transferência de ácidos nucleicos, composição, utilização de um agente de transferência, e, processos de transferência de ácidos nucleicos nas células, de preparação de uma composição e de tratamento de doenças.
BR9811478A (pt) Composições de polìmero-ácido tânico para a liberação controlada de agentes farmacêuticos particularmente na cavidade oral
BR9809506A (pt) Composto, composição, utilização de um composto, e, processos para preparação de um composto e para transferência de ácidos nucleicos para o interior das células
BR9912275A (pt) Formulação de bioimplante
BR9809492A (pt) Composição farmacêutica aquosa injetável, e, processo para a preparação da mesma
BR9808140A (pt) Formulação unitária
BR9914393A (pt) Método para a obtenção de beta-ngf ativo
ATE31300T1 (de) Imidazol-2-yl-mercaptoalkansaeuren, verfahren zu deren herstellung und pharmazeutische formulierungen welche diese enthalten.
CN101945886A (zh) 采用含有脂质修饰半胱氨酸的肽的局部组合物和方法
TR200100897T2 (tr) Lipid metabolizma bozukluklarının tedavisinde safra asitleriyle bağlı propanolamin türevleri.
BR9915897A (pt) Agentes de transferência de ácidos nucleicos, composição, utilização de um agente de transferência e processos de tratamento de corpo humano ou animal e de transferência de ácidos nucleicos.
PT1178960E (pt) Analogos da vitamina d e sua utilizacao farmaceutica
NO20001812D0 (no) Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav
PT1100481E (pt) Formulacoes farmaceuticas compreendendo dipropionato de beclometasona para o tratamento de doencas inflamatorias do intestino
BR0215843A (pt) Composições depósitos injetáveis e seus usos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.